Format

Send to

Choose Destination
Ann Surg Oncol. 2019 Aug;26(8):2595-2604. doi: 10.1245/s10434-019-07378-9. Epub 2019 May 20.

RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.

Author information

1
Oncologic and Pancreatic Surgery Unit, University Hospital Reina Sofıa, Córdoba, Spain. alvaroarjona@hotmail.com.
2
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, University Hospital Reina Sofıa, Córdoba, Spain. alvaroarjona@hotmail.com.
3
Oncologic and Pancreatic Surgery Unit, University Hospital Reina Sofıa, Córdoba, Spain.
4
Peritoneal Surface Malignancy Program, Department of Surgery, Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy.
5
Department of Surgery and Transplantation, University Hospital of Zurich, Zurich, Switzerland.
6
Surgery Department, Unit of Peritoneal Oncologic Surgery, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
7
Department of Surgery, Instituto Valenciano de Oncología, Valencia, Spain.
8
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
9
Departamento De Cirugía General, Unidad De Cirugía De La Carcinomatosis Peritoneal, Virgen De La Arrixaca University Hospital, Murcia, Spain.
10
Unit of Peritoneal Oncologic Surgery and Colorectal Surgery, Hospital University Nuestra Señora de la Candelaria, Tenerife, Spain.
11
Unit of Oncologic and Pancreatic Surgery, Hospital Son Spaces, Palma de Mallorca, Spain.
12
Division of Surgical Oncology, The University of Illinois at Chicago Hospital and Health Sciences System, Chicago, IL, USA.
13
Department of Surgery, Donostia Hospital, San Sebastián, Spain.
14
Gastroenterology Service, Liver Transplantation Unit, Rio Hortega Hospital, Valladolid, Spain.
15
Department of Surgery, H.U. Gran Canaria Dr. Negrín, Canarias, Spain.
16
Department of Surgical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey.
17
Department of Surgical Oncology, University Hospital Ciudad Real, Ciudad Real, Spain.
18
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, University Hospital Reina Sofıa, Córdoba, Spain.

Abstract

BACKGROUND:

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently the most accepted treatment for peritoneal metastases from colorectal cancer. Restrictive selection criteria are essential to obtain the best survival benefits for this complex procedure. The most widespread score for patient selection, the peritoneal surface disease severity score (PSDSS), does not include current biological factors that are known to influence on prognosis. We investigated the impact of including RAS mutational status in the selection criteria for these patients.

METHODS:

We studied the risk factors for survival by multivariate analysis using a prospective database of consecutive patients with carcinomatosis from colorectal origin treated by CRS and HIPEC in our unit from 2009 to 2017. The risk factors obtained were validated in a multicentre, international cohort, including a total of 520 patients from 15 different reference units.

RESULTS:

A total of 77 patients were selected for local análisis. Only RAS mutational status (HR: 2.024; p = 0.045) and PSDSS stage (HR: 2.90; p = 0.009) were shown to be independent factors for overall survival. Early PSDSS stages I and II associated to RAS mutations impaired their overall survival with no significant differences with PSDSS stage III overall survival (p > 0.05). These results were supported by the international multicentre validation.

CONCLUSIONS:

By including RAS mutational status, we propose an updated RAS-PSDSS score that outperforms PSDSS alone providing a quick and feasible preoperative assessment of the expected overall survival for patients with carcinomatosis from colorectal origin undergone to CRS + HIPEC.

PMID:
31111351
DOI:
10.1245/s10434-019-07378-9

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center